Cancer
Conditions
Interventions
control group:Take Mecobalamin tablets orally, 1 tablet each time, 3 times a day for 4 weeks.
2/100Hz EA Group:the treatment method was the same as that of 2Hz EA group, and the EA frequency was changed to 2/100Hz.
100Hz EA Group:the treatment method was the same as that of 2Hz EA group, while the EA frequency was changed to 100Hz.
2Hz EA Group:Bilateral Hegu(LI4), Houxi(SI3), Waiguan(SJ5), Quchi(LI11) and Baxie(EX-UE9) acupoints were taken in the upper limbs, and bilateral Zusanli(ST36), Yinlingquan(GB34), Yanglingquan(SP9), Sa
Upper limb EA connects Waiguan(SJ5) and Hegu(LI4) points
Lower lim
Sponsors
Zhejiang Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: (1) Over 18 and under 70 years old, and the expected survival time was = 1 year; (2) Pathological diagnosis was malignant tumor, and peripheral neurotoxicity above grade 1 occurred after chemotherapy with platinum, paclitaxel and vinblastine; (3) Have daily living ability, no hearing loss, and can cooperate independently to complete all examinations; (4) No serious heart, liver, brain, kidney and other diseases, Karnofsky functional status score (KPS)>60; (5) Clear consciousness without mental illness or cognitive impairmen; (6) Signed the written informed consent form for the clinical trial.
Exclusion criteria
Exclusion criteria: (1) Diagnoses of relatively severe systemic diseases (cardiovascular disease, acute infectious disease, haematopathy, endocrinopathy, allergy or methysis); (2) Diagnoses of depression, anxiety, schizophrenia orother severe mental disorders; (3) Diagnosed as peripheral neuropathy caused by other causes, such as peripheral nerve injury or diabetic peripheral neuropathy; (4) Pregnant and lactating women; (5) Alcohol and/or other drug abuse or dependen; (6) Participating in other clinical trials of acupuncture or drugs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Peripheral neurotoxicity was assessed according to NCI CTCAE version 5.0;Patient peripheral neurotoxicity Self Rating Questionnaire (PNQ); | — |
Secondary
| Measure | Time frame |
|---|---|
| NCV measurement;EORTC quality of life scale (QLQ-C30); | — |
Countries
China
Contacts
Public ContactLu Chaos
Outcome results
None listed